Cargando…

Glucagon receptor antagonist upregulates circulating GLP-1 level by promoting intestinal L-cell proliferation and GLP-1 production in type 2 diabetes

OBJECTIVE: Glucagon receptor (GCGR) blockage improves glycemic control and increases circulating glucagon-like peptide-1 (GLP-1) level in diabetic animals and humans. The elevated GLP-1 has been reported to be involved in the hypoglycemic effect of GCGR blockage. However, the source of this elevatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lang, Shan, Yang, Jin, Yang, Kun, Gu, Liangbiao, Cui, Xiaona, Wei, Tianjiao, Liu, Junling, Le, Yunyi, Wang, Haining, Wei, Rui, Hong, Tianpei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Emerging Technologies, Pharmacology and Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059498/ https://www.ncbi.nlm.nih.gov/pubmed/32139602 http://dx.doi.org/10.1136/bmjdrc-2019-001025

Ejemplares similares

Glucagon Acting at the GLP-1 Receptor Contributes to β-Cell Regeneration Induced by Glucagon Receptor Antagonism in Diabetic Mice
por: Wei, Tianjiao, et al.
Publicado: (2023)

Antagonistic Glucagon Receptor Antibody Promotes α-Cell Proliferation and Increases β-Cell Mass in Diabetic Mice
por: Wei, Rui, et al.
Publicado: (2019)

Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs)
por: Desouza, Cyrus, et al.
Publicado: (2020)

Glucagon, GLP-1 and Thermogenesis
por: González-García, Ismael, et al.
Publicado: (2019)

Effect of Repeated Glucagon Doses on Hepatic Glycogen in Type 1 Diabetes: Implications for a Bihormonal Closed-Loop System
por: Castle, Jessica R., et al.
Publicado: (2015)

Pro-α-cell-derived β-cells contribute to β-cell neogenesis induced by antagonistic glucagon receptor antibody in type 2 diabetic mice
por: Cui, Xiaona, et al.
Publicado: (2022)

Glucagon-like peptide 1 (GLP-1)
por: Müller, T.D., et al.
Publicado: (2019)

An Incidental Finding of a Glucagon-Like Peptide 1 (GLP-1)-Induced Acute Kidney Injury: A Case Report
por: Aleman Espino, Andy, et al.
Publicado: (2023)

Allosteric Modulation of the Activity of the Glucagon-like Peptide-1 (GLP-1) Metabolite GLP-1 9–36 Amide at the GLP-1 Receptor
por: Li, Naichang, et al.
Publicado: (2012)

GLP-1R–Targeting Magnetic Nanoparticles for Pancreatic Islet Imaging
por: Wang, Ping, et al.
Publicado: (2014)

Serum levels of glucagon-like peptide (GLP)-1 and GLP-2 in patients with Hashimoto's thyroiditis
por: Jin, Yue, et al.
Publicado: (2015)

Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK
por: Weiss, Tracey, et al.
Publicado: (2022)

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021)

Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output
por: Liu, Junling, et al.
Publicado: (2019)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

Comparison of a ready-to-use liquid glucagon injection administered by autoinjector to glucagon emergency kit for the symptomatic relief of severe hypoglycemia: two randomized crossover non-inferiority studies
por: Christiansen, Mark P, et al.
Publicado: (2021)

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events
por: Lingvay, Ildiko, et al.
Publicado: (2020)

Ultrastructural Study on Colocalization of Glucagon-Like Peptide (GLP)-1 with GLP-2 in Chicken Intestinal L-Cells
por: NISHIMURA, Kei, et al.
Publicado: (2013)

[Gly²]-GLP-2, But Not Glucagon or [D-Ala²]-GLP-1, Controls Collagen Crosslinking in Murine Osteoblast Cultures
por: Mieczkowska, Aleksandra, et al.
Publicado: (2021)

GLP-1/glucagon receptor co-agonism for treatment of obesity
por: Sánchez-Garrido, Miguel A., et al.
Publicado: (2017)

Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment
por: Orban, Tihamer, et al.
Publicado: (2014)

Inhaled Formoterol Diminishes Insulin-Induced Hypoglycemia in Type 1 Diabetes
por: Belfort-DeAguiar, Renata D., et al.
Publicado: (2015)

Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: a pilot randomized controlled and add-on study
por: Shima, Kosuke Robert, et al.
Publicado: (2018)

The Human GLP-1 Analog Liraglutide and the Pancreas: Evidence for the Absence of Structural Pancreatic Changes in Three Species
por: Nyborg, Niels C.B., et al.
Publicado: (2012)

The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice
por: Ørgaard, Anne, et al.
Publicado: (2017)

Plasma levels of glucagon but not GLP-1 are elevated in response to inflammation in humans
por: Modrzynska, Justyna, et al.
Publicado: (2021)

Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection()()
por: Ussher, John R., et al.
Publicado: (2014)

The Role of Glucagon-Like Peptide 1 (GLP1) in Type 3 Diabetes: GLP-1 Controls Insulin Resistance, Neuroinflammation and Neurogenesis in the Brain
por: Bae, Choon Sang, et al.
Publicado: (2017)

Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual β-Cell Function
por: Kielgast, Urd, et al.
Publicado: (2011)

GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1α Mutation Carriers
por: Christensen, Alexander S., et al.
Publicado: (2020)

Overnight Glucose Control With an Automated, Unified Safety System in Children and Adolescents With Type 1 Diabetes at Diabetes Camp
por: Ly, Trang T., et al.
Publicado: (2014)

Performance of the FreeStyle Libre Flash glucose monitoring system in patients with type 1 and 2 diabetes mellitus
por: Fokkert, M J, et al.
Publicado: (2017)

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
por: Saraiva, Francisco Kerr, et al.
Publicado: (2014)

Modulation of Cardiac Ventricular Excitability by GLP-1 (Glucagon-Like Peptide-1)
por: Ang, Richard, et al.
Publicado: (2018)

Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
por: Ja’arah, Daria, et al.
Publicado: (2021)

Acute Metabolic Effects of Exenatide in Patients With Type 1 Diabetes With and Without Residual Insulin to Oral and Intravenous Glucose Challenges
por: Ghazi, Tara, et al.
Publicado: (2014)

Safety of Nighttime 2-Hour Suspension of Basal Insulin in Pump-Treated Type 1 Diabetes Even in the Absence of Low Glucose
por: Sherr, Jennifer L., et al.
Publicado: (2014)

Preexisting Insulin Autoantibodies Predict Efficacy of Otelixizumab in Preserving Residual β-Cell Function in Recent-Onset Type 1 Diabetes
por: Demeester, Simke, et al.
Publicado: (2015)

Feasibility of overnight closed-loop therapy in young children with type 1 diabetes aged 3–6 years: comparison between diluted and standard insulin strength
por: Elleri, Daniela, et al.
Publicado: (2014)

Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
por: Xu, Dan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bt7fsmrs1e2gvoe9s4eghhp503